Recombinant production of human papillomavirus type 16 E6 and E7 vaccine antigens in Chlamydomonas reinhardtii
Journal of Biotechnology · 2026-09 · 417 · 265-273
DOI: 10.1016/j.jbiotec.2026.06.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biotechnology, 2026-09. Verfasst von Shubham Kumar Dubey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh 484887, India. Hauptthemen laut MEDLINE: Chlamydomonas reinhardtii, Oncogene Proteins, Viral, Papillomavirus E7 Proteins, Repressor Proteins. Die Arbeit nennt 46 Literaturangaben. Gefördert von: India Ministry of Science & Technology Department of Biotechnology, India Ministry of Science & Technology Department of Science and Technology, Indian Council of Medical Research.
Abstract (Originalsprache)
Cervical cancer remains a major health challenge in low- and middle-income countries, where access to prevention and treatment is limited. Persistent infection with high-risk human papillomavirus (HPV), particularly HPV16, drives malignant transformation through the continuous expression of the viral oncoproteins E6 and E7. These tumor-specific antigens are promising targets for therapeutic vaccine development, but scalable and affordable production systems for recombinant HPV antigens are still lacking. This study establishes Chlamydomonas reinhardtii as a microalgal platform for producing HPV16 E6 and E7 proteins. Codon-optimized sequences encoding HPV16 E6 (519bp) and E7 (481bp) were integrated into the nuclear genome of C. reinhardtii using electroporation-mediated transformation. Protein analysis by SDS-PAGE and immunoblotting detected recombinant E6 (~18kDa) and E7 (~11kDa) at their predicted molecular weights, confirming successful translation. Critically, LC-MS/MS analysis identified multiple high-confidence tryptic peptides corresponding to both HPV antigens, with sequence coverage of 22-35%, providing definitive mass spectrometry-based validation of recombinant protein identity and integrity. These findings show that C. reinhardtii can serve as a scalable, platform for producing clinically relevant HPV16 antigens, supporting its potential application in the development of therapeutic vaccines for HPV-associated cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh 484887, India.
- Department of Biotechnology, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh 484887, India. Electronic address: bhuminath.tripathi@igntu.ac.in.
Förderung
- India Ministry of Science & Technology Department of Biotechnology
- India Ministry of Science & Technology Department of Science and Technology
- Indian Council of Medical Research
Zitieren
APA
Dubey, S. K., Upadhyay, M., Singh, V., & Tripathi, B. N. (2026). Recombinant production of human papillomavirus type 16 E6 and E7 vaccine antigens in Chlamydomonas reinhardtii. Journal of Biotechnology, 417, 265-273. https://doi.org/10.1016/j.jbiotec.2026.06.013
Vancouver
Dubey SK, Upadhyay M, Singh V, Tripathi BN. Recombinant production of human papillomavirus type 16 E6 and E7 vaccine antigens in Chlamydomonas reinhardtii. Journal of Biotechnology. 2026;417:265-273. doi:10.1016/j.jbiotec.2026.06.013
BibTeX
@article{Dubey2026,
author = {Dubey, Shubham Kumar and Upadhyay, Manu and Singh, Vijetna and Tripathi, Bhumi Nath},
title = {Recombinant production of human papillomavirus type 16 E6 and E7 vaccine antigens in Chlamydomonas reinhardtii},
journal = {Journal of Biotechnology},
year = {2026},
volume = {417},
pages = {265--273},
doi = {10.1016/j.jbiotec.2026.06.013}
}
EUVIMED